Browsing by Author "Ashenafi Assefa"
Now showing 1 - 3 of 3
Results Per Page
Sort Options
Item Malaria Elimination in Ethiopia: Relevance of Advanced Molecular/Diagnostic Tools in Epidemiological Studies.(Addis Abeba University, 2019-11) Ashenafi Assefa; Ahmed Ali; Wakgari DeressaBackground: Malaria is still among the major diseases of public health importance in Ethiopia. Ethiopia presents a diversified ecological situation, resulting in a highly variable eco-epidemiology of malaria. Following the scale-up of antimalarial interventions in the past two decades, malaria burden has significantly declined leading to the National Malaria Control Program (NMCP) in Ethiopia to reembark on a strategy for step by step nationwide malaria elimination. Learning from the failed malaria elimination endeavors of the 1960s, achieving such an ambitious target, given the complicated eco-epidemiology of malaria in Ethiopia may require several inputs and evidences. Measures of malaria burden and transmission dynamics using conventional diagnostic methods [microscopy and Rapid Diagnostic tests (RDTs)] may be incomplete, particularly, in low and seasonal transmission settings, where few infections are detected. Unlike most parts of Africa, P.falciparum and P. vivax co-exist in Ethiopia. Malaria elimination requires determining the actual burden, distribution as well as detection and cleaning of all forms of malaria infection. The knowledge gap in the occurrence, prevalence and distribution of Glucose-6-PhosphateDehydrogenase (G6PD) deficiency has been a limiting factor for radical cure of relapsing malaria and transmission interruption. The group of drugs within 8-aminoquinolines, such as Primaquine and Tafenaquine, are the only available treatment of relapsing malaria. Eight-aminoquinolines can induce severe hemolysis in G6PD deficient individuals. The study used advanced tools to investigate the epidemiological risk factors relevant for malaria elimination. Objective: This study used serology and molecular methods to describe the malaria (Plasmodium spp) burdenand distribution, as well as to determine G6PD deficiency prevalence and allelic types, in order toproduce reliable evidence for malaria elimination in Ethiopia. Methodology:Dried blood spot (DBS) samples collected in 2011 and 2015 as part of the national householdMalaria Indicator Surveys (MIS) were used. The Ethiopian Malaria Indicator Surveys (EMISs) utilized a multi-stage cross sectional surveys representating the various malaria epidemiologicalsettings in Ethiopia. EMIS-2015 samples were investigated using bead-based multiplex assays forIgG antibodies for six Plasmodium spp antigens: four human malaria species-specific merozoitesurface protein 1 19kD antigens (MSP-1) and apical membrane antigen 1 (AMA-1) for P.falciparum and P. vivax. Seroprevalence was estimated by age group, elevation, and administrative regions. Sero conversion rates were estimated using a reversible catalytic model fitted with maximum likelihood method. Sub samples of EMIS-2015 from three administrative regions(Amhara, Tigray and Benishangul Gumuz regions) were screened by Microscopy, RDTs and nested Polymerase Chain Reaction (nPCR) for malaria parasites and results were compared to determine prevalence of sub patent infections. A randomly selected subset of samples from EMIS2011were genotyped by polymerase chain reaction-restriction fragment length polymorphism(PCR-RFLP) technique and three common G6PD genotype variants: G6PD*A (A376G),G6PD*A- (G202A) and Mediterranean (C563T) were investigated. Data were analyzed using Stata 13 (College Station, USA). Serology data were generated from amultiplex instrument as Mean Floruescent Intensity minus background (MFI-bg). To dichotomizeseropositivity, log-transformed MFI-bg values were fitted to a two-component Finite MixtureModel (FMM) by the FMM procedure with normal distribution and maximum likelihood estimation outputs. A sero positivity cutoff value was determined by the mean MFI-bg value of the first (assumed sero negative) component plus three standard deviations. Plasmodium falciparumand P. vivax seropositivity were defined as being positive for either or both MSP-1 and AMA-1 antigens. Species specific MSP-1 antigens were used for P. malariae and P. ovale seropositivity. EMISs sampling weights were used to ensure the representativeness of the samples tested to the study population. Adjustments were made by region, elevation, and age group. Linear and multiple logistic regression models with 95% confidence intervals (CI) were employed to determine theassociation of risk factors with Plasmodium spp infection. Differences in distributions were evaluated using Chi square (χ2) test with P value < 0.05 considered significant. Spatial analysis and geographical mapping were done using QGIS and ArcGIS software’s. Main Findings: National sero prevalence for antibodies to P. falciparum was 32.1% (95% CI: 29.8-34.4) and 25.0%(95% CI: 22.7-27.3) for P. vivax. Estimated sero prevalence for P. malaria e and P. ovale were8.6% (95% CI: 7.6-9.7) and 3.1% (95% CI: 2.5-3.8), respectively. Sero prevalence estimates were significantly higher at lower elevations (<2000 m) compared to higher elevations (2000-2500 m),for P. falciparum [Adjusted Odds Ratio (aOR) 4.4 (95% CI: 2.7 -7.0), p<0.01].], although evidence was weak for P. vivax [aOR 1.5 (95% CI: 0.9-2.3), p>0.05]]. Among administrative regions, P.falciparum seroprevalence ranged from 11.0% (95% CI: 8.8-13.7) in the Somali to 65.0% (95%CI: 58.0-71.4) in Gambela Region. Seroprevalence for P. vivax ranged from 4.0% (95% CI: 2.66.2)in the Somali to 36.7% (95% CI: 30.0-44.1) in Amhara Region. Models fitted to measuresero conversion rates showed variation nationally and by elevation, region, antigen type and with inspecies. Malaria DNA screening using nPCR from three regions (Amhara, Tigray and Benishangul Gumuz)detected 3.3% (95% CI: 2.7-4.1) positive cases. P. falciparum accounted for 3.1% (95% CI: .53.8),P.vivax0.4%(95%CI:0.2-0.7),mixed (P.falciparum andP.vivax) 0.1% (95%CI:0.0-0.4),mixed(P.falciparumandP.malariae)0.1%(95%CI:0.0-0.3).nPCRdetectednearlythree-fold more positives compared to microscopy. Sixty one percent of the nPCR positive cases were from Benishangul Gumuz Region. The G6PD genotyping study showed the more severe G6PD deficiency allelictypes,G202A(A-) and C563T (Mediterranean), to be absent in the current study. A national prevalence of 8.1%G6PD*A (A376G) mutation variants was observed with regional variation, with highest prevalence observed in Tigray Region (13.7%) to none in Harari. Of the G6PD*A (A376G), 31%were hemizygous males and 62.1% and 6.8% were heterozygous and homozygous females, respectively. Conclusion and Recommendations: The current study used multiplex serology and serological markers to report the malaria exposure burden and transmission intensity of the four human malaria species. The study documented heterogeneity in malaria burden and transmission over different elevations, administrative regions, and age groups. Malaria exposure was by far higher compared to the active infection reported by microscopy and RDTs. P. falciparum sero prevalence increases with decreasing elevation, whereasP. vivax slightly increases with elevation in the study setting up to 2,500 m; showing P. vivax ismore prevalent in highlands compared to P. falciparum. Variation was observed on the spatialdistribution and dynamics of transmission over the regions. The northwestern part of the countryis carrying the largest burden of malaria compared to the east. Among the regions, Gambela and Benishangul-Gumuz had the highest burden of malaria transmission. The current study documented the presence of P. malariae and P. ovale in all administrative regions. Given that P.ovale possesses a hypnozoite stage, its control and elimination requires programmatic attention. The seroprevalenceresults may be used as baseline data for the future malaria elimination efforts and may help the NMPCP in tailoring intervention approaches. The current study documented a considerable proportion of sub patent Plasmodium spp infections undetected by microscopy. Such sub patent infections are potentially infective to mosquitoes, contributing for malaria transmission in addition to their debilitating chronic effect on the individuals affected. Efficient malaria elimination efforts have to address the impact of sub patent infection on transmission and health. In this study, the more severe variants G6PD *A- (G202A) and Mediterranean (C563T) mutations were not observed. The G6PD *A (A376G) mutation observed is a mild variant resulting in close to normal (85%) enzyme activity of a non-deficient person, without significant clinical manifestations of G6PD deficiency related hemolysis. This study investigated three of the mostimportant and potentially expected mutation types in the study area among the hundreds of knownG6PD variants worldwide. Although the study cannot definitively conclude the absence of any clinically important G6PD deficiency, it suggests a low risk of hemolysis, and confirms the utility of the recently adopted Primaquine treatment without prior G6PD testing. The risks and benefits of Primaquine radical cure without G6PD testing may need to be further assessed in Ethiopia asthe P. vivax and P. ovale case management is evolving and may incorporate higher dose and shorter course regimens of Primaquine and Tafenoquine. In summary, the current work used advanced serological and molecular diagnostic tools to produce evidence to the epidemiological factors that may be relevant for malaria elimination. It also emphasized the need for assessing and introducing advanced diagnostic techniques, such as PCRand multiplex serology to provide reliable evidences required towards malaria elimination in Ethiopia.Item Therapeutic Efficacy of Artemether-Lumefantrine for the Treatment of Uncomplicated Plasmodium Falciparum Malaria in Metehara Town, Central-East Ethiopia(Addis Ababa University, 2024-03) Mahelet Tesfaye; Hassen Mamo; Ashenafi AssefaMonitoring and identification of drug-resistant Plasmodium falciparum strains is paramount for the fight against malaria. Close surveillance of the emergence and distribution of artemisinin resistance is recommended to guide policy decisions. The efficacy of national first- and second-line anti-malarial treatments should be monitored at least once every 2 years, as recommended in the WHO standard protocol. In Ethiopia, a three-day regime of AL (artemether 20mg and lumefantrine 120mg in each tablet) is the first-line anti-malarial drug for the treatment of uncomplicated P. falciparum malaria since 2004. The objective of this study was assessing the therapeutic efficacy of AL for the treatment of uncomplicated P. falciparum malaria in Metehara, central-east Ethiopia. The study was conducted at Metehara town health center from November 26, 2020 to March 24, 2021. One-arm prospective evaluation was conducted on the clinical and parasitological responses to directly observed treatment for uncomplicated P. falciparum malaria. During the study regime, 80 patients were screened and 73(50 male and 30 female) participants completed the follow-up and among those 14 patients were <5 age, 25 between the age 5-14 and 34 were >14. The overall cure rate was 100% (73/73; 95% CI: 95.1-100.0) with no early treatment failure, late treatment failure, and late parasitological failure as in Kaplan–Meier analyses all participants completely recovered from parasitemia and fever on day (D) 3; the asexual parasite clearance rate was 100% and clinical symptoms resolved quickly. Gametocyte carriage was reduced from 8.4% on D0 to 1% on D3 and complete clearance was achieved on D7. There was no serious adverse event. In the study location, AL was effective for treating uncomplicated P. falciparum malaria.Item Therapeutic Efficacy of Artemether-Lumefantrine for the Treatment of Uncomplicated Plasmodium Falciparum Malaria in Metehara Town, Central-East Ethiopia(Addis Ababa University, 2024-03) Mahelet Tesfaye; Hassen Mamo; Ashenafi AssefaMonitoring and identification of drug-resistant Plasmodium falciparum strains is paramount for the fight against malaria. Close surveillance of the emergence and distribution of artemisinin resistance is recommended to guide policy decisions. The efficacy of national first- and second-line anti-malarial treatments should be monitored at least once every 2 years, as recommended in the WHO standard protocol. In Ethiopia, a three-day regime of AL (artemether 20mg and lumefantrine 120mg in each tablet) is the first-line anti-malarial drug for the treatment of uncomplicated P. falciparum malaria since 2004. The objective of this study was assessing the therapeutic efficacy of AL for the treatment of uncomplicated P. falciparum malaria in Metehara, central-east Ethiopia. The study was conducted at Metehara town health center from November 26, 2020 to March 24, 2021. One-arm prospective evaluation was conducted on the clinical and parasitological responses to directly observed treatment for uncomplicated P. falciparum malaria. During the study regime, 80 patients were screened and 73(50 male and 30 female) participants completed the follow-up and among those 14 patients were <5 age, 25 between the age 5-14 and 34 were >14. The overall cure rate was 100% (73/73; 95% CI: 95.1-100.0) with no early treatment failure, late treatment failure, and late parasitological failure as in Kaplan–Meier analyses all participants completely recovered from parasitemia and fever on day (D) 3; the asexual parasite clearance rate was 100% and clinical symptoms resolved quickly. Gametocyte carriage was reduced from 8.4% on D0 to 1% on D3 and complete clearance was achieved on D7. There was no serious adverse event. In the study location, AL was effective for treating uncomplicated P. falciparum malaria.